1
|
Flores J, Takvorian PM, Weiss LM, Cali A, Gao N. Human microsporidian pathogen Encephalitozoon intestinalis impinges on enterocyte membrane trafficking and signaling. J Cell Sci 2021; 134:jcs.253757. [PMID: 33589497 DOI: 10.1242/jcs.253757] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2020] [Accepted: 02/01/2021] [Indexed: 12/23/2022] Open
Abstract
Microsporidia are a large phylum of obligate intracellular parasites. Approximately a dozen species of microsporidia infect humans, where they are responsible for a variety of diseases and occasionally death, especially in immunocompromised individuals. To better understand the impact of microsporidia on human cells, we infected human colonic Caco2 cells with Encephalitozoon intestinalis, and showed that these enterocyte cultures can be used to recapitulate the life cycle of the parasite, including the spread of infection with infective spores. Using transmission electron microscopy, we describe this lifecycle and demonstrate nuclear, mitochondrial and microvillar alterations by this pathogen. We also analyzed the transcriptome of infected cells to reveal host cell signaling alterations upon infection. These high-resolution imaging and transcriptional profiling analysis shed light on the impact of the microsporidial infection on its primary human target cell type.This article has an associated First Person interview with the first authors of the paper.
Collapse
Affiliation(s)
- Juan Flores
- Department of Biological Sciences, Rutgers University, Newark, New Jersey 07102, USA
| | - Peter M Takvorian
- Department of Biological Sciences, Rutgers University, Newark, New Jersey 07102, USA.,Departments of Medicine and Pathology, Albert Einstein College of Medicine Bronx, New York 10461, USA
| | - Louis M Weiss
- Departments of Medicine and Pathology, Albert Einstein College of Medicine Bronx, New York 10461, USA
| | - Ann Cali
- Department of Biological Sciences, Rutgers University, Newark, New Jersey 07102, USA
| | - Nan Gao
- Department of Biological Sciences, Rutgers University, Newark, New Jersey 07102, USA
| |
Collapse
|
2
|
Abstract
BACKGROUND Although chimeric antigen receptor (CAR) T-cell therapy targeting antigens expressed in refractory and relapsed non-Hodgkin B-cell lymphoma, such as CD19 and CD22, has achieved encouraging clinical effects, some patients fail to attain remission, or relapse after CAR T-cell therapy, which has been ascribed to the loss of the target antigens. OBJECTIVE To evaluate CD79b as an alternative target for CAR T-cell B-cell lymphoma therapy. PATIENT AND METHODS The expression of CD79b in different B-cell lymphomas was determined. Anti-CD79b CAR T-cells expressing one of two different CARs were generated, and a series of in vitro and in vivo experiments were conducted to assess the CAR T-cell function. RESULTS We found that CD79b was extensively expressed on the tumor cells of patients with various types of lymphoma regardless of stage, subtype, and cytogenetic and molecular features. Anti-CD79b CAR T-cells were highly specific and effective for the treatment of B-cell lymphomas. CONCLUSIONS Our data indicate that CD79b could be used as a target for CAR T-cell therapy of B-cell lymphomas, and further clinical development is warranted.
Collapse
|
3
|
Stopforth RJ, Oldham RJ, Tutt AL, Duriez P, Chan HTC, Binkowski BF, Zimprich C, Li D, Hargreaves PG, Cong M, Reddy V, Leandro MJ, Cambridge G, Lux A, Nimmerjahn F, Cragg MS. Detection of Experimental and Clinical Immune Complexes by Measuring SHIP-1 Recruitment to the Inhibitory FcγRIIB. JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 2018; 200:1937-1950. [PMID: 29351998 PMCID: PMC5837011 DOI: 10.4049/jimmunol.1700832] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/08/2017] [Accepted: 12/20/2017] [Indexed: 12/16/2022]
Abstract
Fc γ receptors (FcγR) are involved in multiple aspects of immune cell regulation, are central to the success of mAb therapeutics, and underpin the pathology of several autoimmune diseases. However, reliable assays capable of accurately measuring FcγR interactions with their physiological ligands, IgG immune complexes (IC), are limited. A method to study and detect IC interactions with FcγRs was therefore developed. This method, designed to model the signaling pathway of the inhibitory FcγRIIB (CD32B), used NanoLuc Binary Interaction Technology to measure recruitment of the Src homology 2 domain-containing inositol phosphatase 1 to the ITIM of this receptor. Such recruitment required prior cross-linking of an ITAM-containing activatory receptor, and evoked luciferase activity in discrete clusters at the cell surface, recapitulating the known biology of CD32B signaling. The assay detected varying forms of experimental IC, including heat-aggregated IgG, rituximab-anti-idiotype complexes, and anti-trinitrophenol-trinitrophenol complexes in a sensitive manner (≤1 μg/ml), and discriminated between complexes of varying size and isotype. Proof-of-concept for the detection of circulating ICs in autoimmune disease was provided, as responses to sera from patients with systemic lupus erythematosus and rheumatoid arthritis were detected in small pilot studies. Finally, the method was translated to a stable cell line system. In conclusion, a rapid and robust method for the detection of IC was developed, which has numerous potential applications including the monitoring of IC in autoimmune diseases and the study of underlying FcγR biology.
Collapse
Affiliation(s)
- Richard J Stopforth
- Antibody and Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, United Kingdom
| | - Robert J Oldham
- Antibody and Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, United Kingdom
| | - Alison L Tutt
- Antibody and Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, United Kingdom
| | - Patrick Duriez
- Southampton Experimental Cancer Medicine/Cancer Research U.K. Centre, Protein Core Facility, Cancer Sciences Unit, Southampton General Hospital, Southampton SO16 6YD, United Kingdom
| | - H T Claude Chan
- Antibody and Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, United Kingdom
| | | | | | - Dun Li
- Promega Corp., Fitchburg, WI 53711
| | - Philip G Hargreaves
- Promega UK Ltd., Southampton Science Park, Southampton SO16 7NS, United Kingdom
| | - Mei Cong
- Promega Corp., Fitchburg, WI 53711
| | - Venkat Reddy
- Division of Medicine, Centre for Rheumatology, University College London, London WC1E 6JF, United Kingdom; and
| | - Maria J Leandro
- Division of Medicine, Centre for Rheumatology, University College London, London WC1E 6JF, United Kingdom; and
| | - Geraldine Cambridge
- Division of Medicine, Centre for Rheumatology, University College London, London WC1E 6JF, United Kingdom; and
| | - Anja Lux
- Department of Biology, University of Erlangen-Nuremberg, 91058 Erlangen, Germany
| | - Falk Nimmerjahn
- Department of Biology, University of Erlangen-Nuremberg, 91058 Erlangen, Germany
| | - Mark S Cragg
- Antibody and Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, United Kingdom;
| |
Collapse
|
4
|
Adzavon YM, Zhao P, Zhang X, Liu M, Lv B, Yang L, Zhang X, Xie F, Zhang M, Ma J, Ma X. Genes and pathways associated with the occurrence of malignancy in benign lymphoepithelial lesions. Mol Med Rep 2017; 17:2177-2186. [PMID: 29207199 PMCID: PMC5783467 DOI: 10.3892/mmr.2017.8149] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2017] [Accepted: 09/06/2017] [Indexed: 12/24/2022] Open
Abstract
There is increasing evidence concerning the occurrence of malignant lymphoma among people suffering from Mikulicz disease, also termed benign lymphoepithelial lesion (BLEL) and immunoglobulin G4-associated disease. However, the underlying molecular mechanism of the malignant transformation remains unclear. The present study aimed to investigate the gene expression profile between BLEL and malignant lymphoepithelial lesion (MLEL) conditions using tissue microarray analysis, to identify genes and pathways which may be associated with the risk of malignant transformation. Comparing gene expression profiles between BLEL tissues (n=13) and MLEL (n=14), a total of 1,002 differentially expressed genes (DEGs) were identified including 364 downregulated and 638 upregulated DEGs in BLEL. The downregulated DEGs in BLEL were frequently associated with immune-based functions, immune cell differentiation, proliferation and survival, and metabolic functions, whereas the upregulated DEGs were primarily associated with organ, gland and tissue developmental processes. The B cell receptor signaling pathway, the transcription factor p65 signaling pathway, low affinity immunoglobulin γ Fc region receptor II-mediated phagocytosis, the high affinity immunoglobulin ε receptor subunit γ signaling pathway and Epstein-Barr virus infection, and pathways in cancer, were the pathways associated with the downregulated DEGs. The upregulated DEGs were associated with three pathways, including glutathione metabolism, salivary secretion and mineral absorption pathways. These results suggested that the identified signaling pathways and their associated genes may be crucial for understanding the molecular mechanisms underlying malignant transformation from BLEL, and they may be considered to be markers for predicting malignancy among the BLEL group.
Collapse
Affiliation(s)
- Yao Mawulikplimi Adzavon
- College of Life Science and Bio‑engineering, Beijing University of Technology, Beijing 100124, P.R. China
| | - Pengxiang Zhao
- College of Life Science and Bio‑engineering, Beijing University of Technology, Beijing 100124, P.R. China
| | - Xin Zhang
- College of Life Science and Bio‑engineering, Beijing University of Technology, Beijing 100124, P.R. China
| | - Mengyu Liu
- College of Life Science and Bio‑engineering, Beijing University of Technology, Beijing 100124, P.R. China
| | - Baobei Lv
- College of Life Science and Bio‑engineering, Beijing University of Technology, Beijing 100124, P.R. China
| | - Linqi Yang
- College of Life Science and Bio‑engineering, Beijing University of Technology, Beijing 100124, P.R. China
| | - Xujuan Zhang
- College of Life Science and Bio‑engineering, Beijing University of Technology, Beijing 100124, P.R. China
| | - Fei Xie
- College of Life Science and Bio‑engineering, Beijing University of Technology, Beijing 100124, P.R. China
| | - Mingzi Zhang
- Department of Plastic Surgery, Peking Union Medical College Hospital, Beijing 100730, P.R. China
| | - Jianmin Ma
- Beijing Ophthalmology and Vision Science Key Lab, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, P.R. China
| | - Xuemei Ma
- College of Life Science and Bio‑engineering, Beijing University of Technology, Beijing 100124, P.R. China
| |
Collapse
|
5
|
Antosz H, Wojciechowska K, Sajewicz J, Choroszyńska D, Marzec-Kotarska B, Osiak M, Pająk N, Tomczak W, Jargiełło-Baszak M, Baszak J. IL-6, IL-10, c-Jun and STAT3 expression in B-CLL. Blood Cells Mol Dis 2015; 54:258-65. [DOI: 10.1016/j.bcmd.2014.11.006] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2014] [Revised: 09/09/2014] [Accepted: 11/13/2014] [Indexed: 11/25/2022]
|
6
|
Therapeutic targeting of the BCR-associated protein CD79b in a TCR-based approach is hampered by aberrant expression of CD79b. Blood 2015; 125:949-58. [DOI: 10.1182/blood-2014-07-587840] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Key Points
B-cell malignancies were efficiently recognized by T cells expressing high-affinity alloHLA-restricted TCRs specific for CD79b. Aberrant expression of CD79b in non–B cells caused unwanted reactivity, rendering CD79b unsuitable for TCR-based immunotherapies.
Collapse
|
7
|
An integrative framework identifies alternative splicing events in colorectal cancer development. Mol Oncol 2013; 8:129-41. [PMID: 24189147 DOI: 10.1016/j.molonc.2013.10.004] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2013] [Revised: 09/17/2013] [Accepted: 10/08/2013] [Indexed: 12/16/2022] Open
Abstract
Alternative splicing (AS) is a common mechanism which creates diverse RNA isoforms from a single gene, potentially increasing protein variety. Growing evidence suggests that this mechanism is closely related to cancer progression. In this study, whole transcriptome analysis was performed with GeneChip Human exon 1.0 ST Array from 80 samples comprising 23 normal colon mucosa, 30 primary colorectal cancer and 27 liver metastatic specimens from 46 patients, to identify AS events in colorectal cancer progression. Differentially expressed genes and exons were estimated and AS events were reconstructed by combining exon-level analyses with AltAnalyze algorithms and transcript-level estimations (MMBGX probabilistic method). The number of AS genes in the transition from normal colon mucosa to primary tumor was the most abundant, but fell considerably in the next transition to liver metastasis. 206 genes with probable AS events in colon cancer development and progression were identified, that are involved in processes and pathways relevant to tumor biology, as cell-cell and cell-matrix interactions. Several AS events in VCL, CALD1, B3GNT6 and CTHRC1 genes, differentially expressed during tumor development were validated, at RNA and at protein level. Taken together, these results demonstrate that cancer-specific AS is common in early phases of colorectal cancer natural history.
Collapse
|
8
|
New insights into pre-BCR and BCR signalling with relevance to B cell malignancies. Nat Rev Immunol 2013; 13:578-91. [DOI: 10.1038/nri3487] [Citation(s) in RCA: 208] [Impact Index Per Article: 18.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
9
|
Park SK, Yang JJ, Oh S, Cho LY, Ma SH, Shin A, Ko KP, Park T, Yoo KY, Kang D. Innate immunity and non-Hodgkin's lymphoma (NHL) related genes in a nested case-control study for gastric cancer risk. PLoS One 2012; 7:e45274. [PMID: 23028900 PMCID: PMC3448653 DOI: 10.1371/journal.pone.0045274] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2012] [Accepted: 08/14/2012] [Indexed: 12/21/2022] Open
Abstract
Objective Genetic variants regulating the host immune system may contribute to the susceptibility for the development of gastric cancer. Little is known about the role of the innate immunity- and non-Hodgkin’s lymphoma (NHL)-related genes for gastric cancer risk. This nested case-control study was conducted to identify candidate genes for gastric cancer risk for future studies. Methods In the Discovery phase, 3,072 SNPs in 203 innate immunity- and 264 NHL-related genes using the Illumine GoldenGateTM OPA Panel were analyzed in 42 matched case-control sets selected from the Korean Multi-center Cancer Cohort (KMCC). Six significant SNPs in four innate immunity (DEFA6, DEFB1, JAK3, and ACAA1) and 11 SNPs in nine NHL-related genes (INSL3, CHMP7, BCL2L11, TNFRSF8, RAD50, CASP7, CHUK, CD79B, and CLDN9) with a permutated p-value <0.01 were re-genotyped in the Replication phase among 386 cases and 348 controls. Odds ratios (ORs) for gastric cancer risk were estimated adjusting for age, smoking status, and H. pylori and CagA sero-positivity. Summarized ORs in the total study population (428 cases and 390 controls) are presented using pooled- and meta-analyses. Results Four SNPs had no heterogeneity across the phases: in the meta-analysis, DEFA6 rs13275170 and DEFB1 rs2738169 had both a 1.3-fold increased odds ratio (OR) for gastric cancer (95% CIs = 1.1–1.6; and 1.1–1.5, respectively). INSL3 rs10421916 and rs11088680 had both a 0.8-fold decreased OR for gastric cancer (95% CIs = 0.7–0.97; and 0.7–0.9, respectively). Conclusions Our findings suggest that certain variants in the innate immunity and NHL-related genes affect the gastric cancer risk, perhaps by modulating infection-inflammation-immunity mechanisms that remain to be defined.
Collapse
Affiliation(s)
- Sue K. Park
- Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Korea
- Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
- Department of Biomedical Sciences, Seoul National University Graduate School, Seoul, Korea
| | - Jae Jeong Yang
- Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Korea
- Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
| | - Sohee Oh
- Department of Statistics, College of Natural Science, Seoul National University, Seoul, Korea
| | - Lisa Y. Cho
- Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Korea
- Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
| | - Seung Hyun Ma
- Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Korea
- Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
| | - Aesun Shin
- National Cancer Control Research Institute, National Cancer Center, Goyang, Korea
| | - Kwang-Pil Ko
- Department of Preventive Medicine, Graduate School of Medicine, Gachon University, Incheon, Korea
| | - Taesung Park
- Department of Statistics, College of Natural Science, Seoul National University, Seoul, Korea
| | - Keun-Young Yoo
- Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Korea
| | - Daehee Kang
- Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Korea
- Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
- Department of Biomedical Sciences, Seoul National University Graduate School, Seoul, Korea
- * E-mail:
| |
Collapse
|
10
|
Enhanced levels of both the membrane-bound and soluble forms of IgM Fc receptor (FcμR) in patients with chronic lymphocytic leukemia. Blood 2011; 118:4902-9. [PMID: 21908424 DOI: 10.1182/blood-2011-04-350793] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023] Open
Abstract
The association of an IgM-Fc receptor (FcμR) with chronic lymphocytic leukemia (CLL) was suggested more than 30 years ago, but its authenticity has never been formally addressed. We examined the expression of the recently identified FcμR by B and T cells in CLL patients using receptor-specific monoclonal antibodies. CLL B cells (CD5(+)/CD19(+)) expressed much higher levels of FcμR on their cell surface than B cells from healthy donors. Such enhanced expression was more evident in immunoglobulin heavy chain variable region (IGHV)-mutated, CD38(-) or early Rai-stage CLL than in IGHV-unmutated, CD38(+), or advanced Rai-stage CLL. Intriguingly, surface FcμR levels also were significantly elevated in the non-CLL B cells (CD5(-)/CD19(+)) and T cells (CD5(+)/CD19(-)), especially in IGHV-mutated CLL. CLL patients also had high serum titers of FcμR compared with healthy donors, and serum FcμR levels correlated significantly with circulating lymphocyte numbers but not with the IGHV mutation status or Rai stage. The serum FcμR was resolved as an ∼ 40-kDa protein, distinct from the cell surface FcμR of ∼ 60 kDa, and it was produced by both CLL B and non-CLL B cells. Mass spectrometric analysis revealed that the serum FcμR is a soluble form of the receptor encoded by an alternatively spliced FcμR transcript. These findings indicate enhanced levels of both membrane-bound and soluble forms of FcμR in CLL patients.
Collapse
|
11
|
Abstract
The B-cell receptor (BCR) is a key survival molecule for normal B cells and for most B-cell malignancies. Recombinatorial and mutational patterns in the clonal immunoglobulin (Ig) of chronic lymphocytic leukemia (CLL) have revealed 2 major IgMD-expressing subsets and an isotype-switched variant, each developing from distinct B-cell populations. Tracking of conserved stereotypic features of Ig variable regions characteristic of U-CLL indicate circulating naive B cells as the likely cells of origin. In CLL, engagement of the BCR by antigen occurs in vivo, leading to down-regulated expression and to an unanticipated modulation of glycosylation of surface IgM, visible in blood cells, especially in U-CLL. Modulated glycoforms of sIgM are signal competent and could bind to environmental lectins. U-CLL cases express more sIgM and have increased signal competence, linking differential signaling responses to clinical behavior. Mapping of BCR signaling pathways identifies targets for blockade, aimed to deprive CLL cells of survival and proliferative signals. New inhibitors of BCR signaling appear to have clinical activity. In this Perspective, we discuss the functional significance of the BCR in CLL, and we describe strategies to target BCR signaling as an emerging therapeutic approach.
Collapse
|
12
|
Packham G, Stevenson F. The role of the B-cell receptor in the pathogenesis of chronic lymphocytic leukaemia. Semin Cancer Biol 2010; 20:391-9. [DOI: 10.1016/j.semcancer.2010.08.004] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2010] [Accepted: 08/25/2010] [Indexed: 12/22/2022]
|
13
|
Zheng B, Fuji RN, Elkins K, Yu SF, Fuh FK, Chuh J, Tan C, Hongo JA, Raab H, Kozak KR, Williams M, McDorman E, Eaton D, Ebens A, Polson AG. In vivo effects of targeting CD79b with antibodies and antibody-drug conjugates. Mol Cancer Ther 2009; 8:2937-46. [DOI: 10.1158/1535-7163.mct-09-0369] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
14
|
Abstract
Zap-70, a crucial molecule for the selective activation of T cells, through its interaction with the zeta chain of the TCR/CD3 complex, is a tyrosine kinase. This well studied molecule has gained a renewed interest upon the demonstration of its transduction and expression in B cells from patients with chronic lymphocytic leukemia. Here the major characteristics of this cytosolic protein are reviewed, as well as its expression in various cell types and some indications about its detection.
Collapse
MESH Headings
- Animals
- Biomarkers, Tumor/analysis
- Biomarkers, Tumor/genetics
- Biomarkers, Tumor/metabolism
- Humans
- Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis
- Leukemia, Lymphocytic, Chronic, B-Cell/genetics
- Leukemia, Lymphocytic, Chronic, B-Cell/metabolism
- Receptors, Antigen, T-Cell/metabolism
- Signal Transduction
- ZAP-70 Protein-Tyrosine Kinase/analysis
- ZAP-70 Protein-Tyrosine Kinase/genetics
- ZAP-70 Protein-Tyrosine Kinase/metabolism
Collapse
|
15
|
ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia. Blood 2007; 111:2685-92. [PMID: 18048647 DOI: 10.1182/blood-2006-12-062265] [Citation(s) in RCA: 115] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
We transduced chronic lymphocytic leukemia (CLL) cells lacking ZAP-70 with vectors encoding ZAP-70 or various mutant forms of ZAP-70 and monitored the response of transduced CLL cells to treatment with F(ab)(2) anti-IgM (anti-mu). CLL cells made to express ZAP-70, a kinase-defective ZAP-70 (ZAP-70-KA(369)), or a ZAP-70 unable to bind c-Cbl (ZAP-YF(292)) experienced greater intracellular calcium flux and had greater increases in the levels of phosphorylated p72(Syk), B-cell linker protein (BLNK), and phospholipase C-gamma, and greater activation of the Ig accessory molecule CD79b in response to treatment with anti-mu than did mock-transfected CLL cells lacking ZAP-70. Transfection of CLL cells with vectors encoding truncated forms of ZAP-70 revealed that the SH2 domain, but not the SH1 domain, was necessary to enhance intracellular calcium flux in response to treatment with anti-mu. We conclude that ZAP-70 most likely acts as an adapter protein that facilitates B-cell receptor (BCR) signaling in CLL cells independent of its tyrosine kinase activity or its ability to interact with c-Cbl.
Collapse
|
16
|
Abstract
Rai and Binet staging of chronic lymphocytic leukaemia (CLL) is being superseded by new prognostic markers. The mutational status of the immunoglobulin variable region heavy-chain genes segregates the disease into more benign and more malignant versions, and has been confirmed as an important prognostic marker in prospective clinical trials. A search for surrogate markers for this difficult-to-perform assay has led to flow cytometric assays for CD38 and ZAP-70 expression, although in both cases there are problems with standardization and interpretation of the assays. A separate pathway of research has revealed two chromosomal aberrations--deletions of 11q and 17p--as important prognostic markers. Fluorescent in-situ hybridization has made their detection readily available. These five markers are in different stages of evaluation, but some of them are ready to be used for risk-adapted therapy in clinical trials. Other assays are in earlier stages of assessment.
Collapse
Affiliation(s)
- Terry J Hamblin
- University of Southampton, c/o Department of Haematology, Royal Bournemouth Hospital, Castle Lane East, Bournemouth BH7 7DW, UK.
| |
Collapse
|
17
|
Abstract
In addition to the important observations relating immunoglobulin (Ig) mutation status to clinical behavior, studies on the Ig expressed in chronic lymphocytic leukemia (CLL) have revealed compelling evidence that antigen selection contributes to the pathogenesis of this disease. CLL cells that use unmutated Ig can generally be distinguished from CLL cells that use Ig with somatic mutations by expression of the 70-kD zeta-associated protein (ZAP-70). ZAP-70 apparently enhances the capacity of CLL cells to respond to antigen, and therefore might play a causal role in the relatively aggressive clinical behavior noted for patients who have CLL cells that use unmutated Ig. Clinical surveys have found that expression of ZAP-70 by CLL cells is apparently a stronger predictor of early disease progression than is the use by CLL cells of unmutated Ig. As such, strategies that respectively monitor or target Ig-receptor signaling in CLL might be very useful in the risk assessment or treatment of this disease.
Collapse
MESH Headings
- Disease Progression
- Humans
- Immunoglobulin Heavy Chains/biosynthesis
- Immunoglobulin Variable Region/biosynthesis
- Leukemia, Lymphocytic, Chronic, B-Cell/genetics
- Leukemia, Lymphocytic, Chronic, B-Cell/immunology
- Receptors, Antigen, B-Cell/genetics
- Receptors, Antigen, B-Cell/immunology
- Signal Transduction
- ZAP-70 Protein-Tyrosine Kinase/physiology
Collapse
Affiliation(s)
- Thomas J Kipps
- UCSD Moores Cancer Center, Division of Hematology/Oncology, Department of Medicine, 3855 Health Sciences Drive, #0820, University of California, San Diego, La Jolla, CA 92093-0820, USA.
| |
Collapse
|
18
|
Artamonova II, Gelfand MS. Comparative Genomics and Evolution of Alternative Splicing: The Pessimists' Science. Chem Rev 2007; 107:3407-30. [PMID: 17645315 DOI: 10.1021/cr068304c] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Irena I Artamonova
- Group of Bioinformatics, Vavilov Institute of General Genetics, RAS, Gubkina 3, Moscow 119991, Russia
| | | |
Collapse
|
19
|
Cajiao I, Sargent R, Elstrom R, Cooke NE, Bagg A, Liebhaber SA. Igbeta(CD79b) mRNA expression in chronic lymphocytic leukaemia cells correlates with immunoglobulin heavy chain gene mutational status but does not serve as an independent predictor of clinical severity. Am J Hematol 2007; 82:712-20. [PMID: 17315213 DOI: 10.1002/ajh.20885] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
The etiology of chronic lymphocytic leukemia (CLL) is poorly understood and its course is highly variable. Somatic hypermutation (SHM) of the immunoglobulin heavy chain (IgV(H)) gene and ZAP70 protein expression have been reported as prognostic indicators. However, these assays are not widely available and their concordance is imperfect. Thus a need exists to identify additional molecular determinants of CLL. The Igbeta (CD79b) subunit of the B cell antigen receptor is essential for B lymphocyte function. Defects in Igbeta expression are implicated in CLL pathogenesis. We have analyzed Igbeta mRNA expression in CLL cells in 40 consecutive patient samples. About 75% of the samples showed the expected decrease of Igbeta surface staining. Igbeta mRNA levels covered a wider range, did not correlate with Igbeta surface staining, but clearly distinguished the normal and CLL lymphocyte populations. Remarkably, Igbeta mRNA levels correlated strongly with SHM; Igbeta mRNA levels in CLL cells were significantly higher in patients with an unmutated IgV(H) gene when compared with those in whom IgV(H) was hypermutated (P = 0.008). In contrast, no correlation was observed between Igbeta mRNA levels and ZAP70 expression. Multiple parameters abstracted from chart reviews were used to estimate severity of CLL in each case. While severity correlated strongly with ZAP70 staining, and to a lesser extent with SHM status, there was no correlation with Igbeta mRNA levels. These data establish a strong linkage between Igbeta mRNA expression and SHM in CLL and highlight the complex relationships between biochemical parameters and clinical status in this disease.
Collapse
MESH Headings
- Adult
- Aged
- Aged, 80 and over
- Alternative Splicing/genetics
- CD79 Antigens/genetics
- CD79 Antigens/metabolism
- Cell Line
- Cell Membrane/metabolism
- Exons/genetics
- Female
- Gene Expression Regulation, Neoplastic/genetics
- Humans
- Immunoglobulin Heavy Chains/genetics
- Immunoglobulin Heavy Chains/immunology
- Immunohistochemistry
- Leukemia, Lymphocytic, Chronic, B-Cell/genetics
- Leukemia, Lymphocytic, Chronic, B-Cell/immunology
- Leukemia, Lymphocytic, Chronic, B-Cell/pathology
- Lymphocytes/metabolism
- Male
- Middle Aged
- Mutation/genetics
- RNA, Messenger/genetics
- ZAP-70 Protein-Tyrosine Kinase/metabolism
Collapse
Affiliation(s)
- Isabela Cajiao
- Department of Genetics, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
| | | | | | | | | | | |
Collapse
|
20
|
Hamblin AD, Hamblin TJ. Functional and prognostic role of ZAP-70 in chronic lymphocytic leukaemia. Expert Opin Ther Targets 2005; 9:1165-78. [PMID: 16300468 DOI: 10.1517/14728222.9.6.1165] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
It has become clear that the heterogeneity of chronic lymphocytic leukaemia (CLL) is not a continuous spectrum, but is bipolar. Originally distinguished by the mutational status of the immunoglobulin variable region genes, the two poles are perhaps better identified by the expression of ZAP-70, a signalling molecule normally utilised by T cells rather than B cells, but anomalously expressed in the more aggressive subtype of CLL. Assaying ZAP-70 expression has become progressively simplified so that a directly stained flow cytometric test is currently being evaluated, and a version of this should shortly be available to routine laboratories. In addition, the understanding of the nature of CLL has been advanced rapidly and this should lead to new, better targeted therapies, which in contrast to the current armoury, will work better for the more malignant variants of CLL than for the more benign. In particular, ZAP-70 is especially attractive because its aberrant expression in tumour cells from the more aggressive forms of CLL requires the chaperoning action of activated heat-shock protein 90, which may be specifically inhibited.
Collapse
MESH Headings
- B-Lymphocytes/metabolism
- Gene Expression Regulation, Neoplastic/physiology
- Humans
- Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis
- Leukemia, Lymphocytic, Chronic, B-Cell/enzymology
- Leukemia, Lymphocytic, Chronic, B-Cell/mortality
- Prognosis
- Signal Transduction/physiology
- Survival Analysis
- ZAP-70 Protein-Tyrosine Kinase/biosynthesis
- ZAP-70 Protein-Tyrosine Kinase/physiology
Collapse
Affiliation(s)
- Angela D Hamblin
- Department of Medicine, Royal Bournemouth Hospital, Bournemouth, BH7 7DW, UK
| | | |
Collapse
|
21
|
Gourley C, Paige AJW, Taylor KJ, Scott D, Francis NJ, Rush R, Aldaz CM, Smyth JF, Gabra H. WWOX mRNA expression profile in epithelial ovarian cancer supports the role of WWOX variant 1 as a tumour suppressor, although the role of variant 4 remains unclear. Int J Oncol 2005; 26:1681-1689. [PMID: 15870886 PMCID: PMC4166600 DOI: 10.3892/ijo.26.6.1681] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
WWOX is a candidate tumour suppressor gene that exhibits LOH or homozygous deletion in several tumour types. As well as the predominant full-length transcript (variant 1) there also exist alternatively spliced transcripts found previously only in malignant tissue. It has been suggested that proteins encoded by these variants may interfere with normal WWOX function in a dominant negative fashion. The most prevalent alternate transcript demonstrated in ovarian cancer is variant 4, which lacks exons 6-8. Here, we report the first comparison of the mRNA expression of WWOX variants 1 and 4 in human ovarian tumours and normal ovaries, and correlate expression with clinical data. We demonstrate significantly lower WWOX variant 1 expression in tumours than in normal ovaries. This reduction was not associated with any specific clinical subgroup. Variant 4 was expressed at low levels, and significantly associated with high grade and advanced stage ovarian cancer. Furthermore, tumours co-expressing variant 4 and relatively high levels of variant 1 showed significantly worse survival than tumours expressing variant 1 alone. However, variant 4 was also frequently identified in non-malignant ovarian tissue. These results support the role of WWOX variant 1 as a suppressor of ovarian tumourigenesis, but the role of variant 4 remains speculative.
Collapse
Affiliation(s)
- C Gourley
- Cancer Research UK and University of Edinburgh, Cancer Research Centre, Crewe Road South, Edinburgh EH4 2XR, Scotland
| | - A J W Paige
- Cancer Research UK and University of Edinburgh, Cancer Research Centre, Crewe Road South, Edinburgh EH4 2XR, Scotland
- Section of Molecular Therapeutics, Department of Cancer Medicine, Imperial College London, Hammersmith Hospital, Du Cane Road, London W12 ONN, UK
| | - K J Taylor
- Cancer Research UK and University of Edinburgh, Cancer Research Centre, Crewe Road South, Edinburgh EH4 2XR, Scotland
| | - D Scott
- Cancer Research UK and University of Edinburgh, Cancer Research Centre, Crewe Road South, Edinburgh EH4 2XR, Scotland
| | - N-J Francis
- Cancer Research UK and University of Edinburgh, Cancer Research Centre, Crewe Road South, Edinburgh EH4 2XR, Scotland
| | - R Rush
- Cancer Research UK and University of Edinburgh, Cancer Research Centre, Crewe Road South, Edinburgh EH4 2XR, Scotland
| | - C M Aldaz
- Department of Carcinogenesis, University of Texas M. D. Anderson Cancer Center, Science Park Research Division, Smithville, TX 78957, USA
| | - J F Smyth
- Cancer Research UK and University of Edinburgh, Cancer Research Centre, Crewe Road South, Edinburgh EH4 2XR, Scotland
| | - H Gabra
- Cancer Research UK and University of Edinburgh, Cancer Research Centre, Crewe Road South, Edinburgh EH4 2XR, Scotland
- Section of Molecular Therapeutics, Department of Cancer Medicine, Imperial College London, Hammersmith Hospital, Du Cane Road, London W12 ONN, UK
| |
Collapse
|
22
|
Brentani RR, Carraro DM, Verjovski-Almeida S, Reis EM, Neves EJ, de Souza SJ, Carvalho AF, Brentani H, Reis LFL. Gene expression arrays in cancer research: methods and applications. Crit Rev Oncol Hematol 2005; 54:95-105. [PMID: 15843092 DOI: 10.1016/j.critrevonc.2004.12.006] [Citation(s) in RCA: 60] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/14/2004] [Indexed: 11/15/2022] Open
Abstract
During the last 5 years, the number of papers describing data obtained by microarray technology increased exponentially with about 3000 papers in 2003. Undoubtedly, cancer is by far the disease that received most of the attention as far as the amount of data generated. As array technology is rather new and highly dependent on bioinformatics, mathematics and statistics, a clear understanding of the knowledge and information derived from array-based experiments is not widely appreciated. We shall review herein some of the issues related to the construction of DNA arrays, quantities and heterogeneity of probes and targets, the consequences of the physical characteristics of the probes, data extraction and data analysis as well as the applications of array technology. Our goal is to bring to the general audience, some of the basics of array technology and its possible application in oncology. By discussing some of the basic aspects of the methodology, we hope to stimulate criticism concerning the conclusions proposed by authors, especially in the light of the very low degree of reproducibility already proven when commercially available platforms were compared . Regardless of its pitfalls, it is unquestionable that array technology will have a great impact in the management of cancer and its applications will range from the discovery of new drug targets, new molecular tools for diagnosis and prognosis as well as for a tailored treatment that will take into account the molecular determinants of a given tumor. Hence, we shall also highlight some of the already available and promising applications of array technology on the day-to-day practice of oncology.
Collapse
|
23
|
Nédellec S, Renaudineau Y, Bordron A, Berthou C, Porakishvili N, Lydyard PM, Pers JO, Youinou P. B cell response to surface IgM cross-linking identifies different prognostic groups of B-chronic lymphocytic leukemia patients. THE JOURNAL OF IMMUNOLOGY 2005; 174:3749-56. [PMID: 15749915 DOI: 10.4049/jimmunol.174.6.3749] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
On the basis of responses to surface IgM (sIgM) cross-linking, B cells from 41 patients with B-chronic lymphocytic leukemia were categorized as 15 nonresponders (group I) and 26 responders (group II). The latter cases were subclassified as those seven where proliferation was induced (subgroup IIa) and the remaining 19 in whom apoptosis occurred (subgroup IIa). Signal disruption in group I was confirmed by the absence of Ca2+ mobilization. Activation of PI3K was constitutive in subgroup IIa, but not in subgroup IIb, and that of Akt induced by anti-mu in subgroup IIa, but not in subgroup IIb. Among the MAPK, ERK was more highly activated relative to p38 in subgroup IIa, whereas activation of p38 predominated over that of ERK in subgroup IIb. For subgroup IIb cells, based on tyrosine phosphorylation and translocation into lipid rafts, sIgM signaling was shown to be enhanced by Zap70. The different consequences of signaling through sIgM were associated with biological prognosis indicators. These included high levels of CD38, lack of mutations in the IgVH chain genes, preferential usage of full-length CD79b, and severe clinical stage. Thus, modification of sIgM-induced signaling could be a therapeutic approach.
Collapse
MESH Headings
- Adult
- Aged
- Aged, 80 and over
- Apoptosis
- B-Lymphocytes/immunology
- B-Lymphocytes/metabolism
- B-Lymphocytes/pathology
- Calcium Signaling
- Case-Control Studies
- Cell Proliferation
- Cross-Linking Reagents
- Female
- Humans
- Immunoglobulin M/metabolism
- In Vitro Techniques
- Leukemia, Lymphocytic, Chronic, B-Cell/classification
- Leukemia, Lymphocytic, Chronic, B-Cell/immunology
- Leukemia, Lymphocytic, Chronic, B-Cell/metabolism
- Leukemia, Lymphocytic, Chronic, B-Cell/pathology
- Male
- Middle Aged
- Mitogen-Activated Protein Kinase Kinases/metabolism
- Phosphorylation
- Prognosis
- Protein-Tyrosine Kinases/metabolism
- Receptors, Antigen, B-Cell/metabolism
- Signal Transduction
- ZAP-70 Protein-Tyrosine Kinase
Collapse
Affiliation(s)
- Steven Nédellec
- Institut de Synergie des Sciences et de la Santé, Brest University Medical School, Brest, France
| | | | | | | | | | | | | | | |
Collapse
|
24
|
Vuillier F, Dumas G, Magnac C, Prevost MC, Lalanne AI, Oppezzo P, Melanitou E, Dighiero G, Payelle-Brogard B. Lower levels of surface B-cell-receptor expression in chronic lymphocytic leukemia are associated with glycosylation and folding defects of the μ and CD79a chains. Blood 2005; 105:2933-40. [PMID: 15591116 DOI: 10.1182/blood-2004-09-3643] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
AbstractLow levels of B-cell-receptor (BCR) expression are the hallmark of tumoral B lymphocytes in B-cell chronic lymphocytic leukemia (B-CLL). These cells also respond inadequately to stimulation through the BCR. This receptor consists of a surface immunoglobulin associated with a CD79a/CD79b heterodimer. We previously showed that the intracellular synthesis of BCR components, from transcription onward, is normal. Here, we investigated the glycosylation status and cellular localization of μ, CD79a, and CD79b chains in 10 CLL patients differing in surface immunoglobulin M (IgM) expression. We reported a severe impairment of the glycosylation and folding of μ and CD79a. These defects were associated with the retention of both chains in the endoplasmic reticulum and lower levels of surface IgM expression. In contrast, no clear impairment of glycosylation and folding was observed for CD79b. No sequence defects were identified for BCR components and for the chaperone proteins involved in BCR folding processes. These data show, for the first time, that lower levels of BCR surface expression observed in CLL are accounted for by an impaired glycosylation and folding of the μ and CD79a chains.
Collapse
MESH Headings
- Aged
- Antigens, CD/chemistry
- Antigens, CD/genetics
- Antigens, CD/metabolism
- B-Lymphocytes/metabolism
- B-Lymphocytes/ultrastructure
- CD79 Antigens
- Dimerization
- Endoplasmic Reticulum/metabolism
- Endoplasmic Reticulum/ultrastructure
- Female
- Gene Expression Regulation, Leukemic
- Glycosylation
- Golgi Apparatus/metabolism
- Golgi Apparatus/ultrastructure
- Humans
- Immunoglobulin M/chemistry
- Immunoglobulin M/genetics
- Immunoglobulin M/metabolism
- Leukemia, Lymphocytic, Chronic, B-Cell/metabolism
- Leukemia, Lymphocytic, Chronic, B-Cell/physiopathology
- Male
- Microscopy, Electron
- Middle Aged
- Molecular Chaperones/metabolism
- Protein Folding
- Receptor Aggregation
- Receptors, Antigen, B-Cell/chemistry
- Receptors, Antigen, B-Cell/genetics
- Receptors, Antigen, B-Cell/metabolism
Collapse
Affiliation(s)
- Françoise Vuillier
- Unité d'Immuno-Hématologie et d'Immunopathologie, Plate-forme de Microscopie Electronique, Institut Pasteur, 28 rue du Dr Roux, 75724 Paris Cedex 15, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Kirschbaum-Slager N, Parmigiani RB, Camargo AA, de Souza SJ. Identification of human exons overexpressed in tumors through the use of genome and expressed sequence data. Physiol Genomics 2005; 21:423-32. [PMID: 15784694 DOI: 10.1152/physiolgenomics.00237.2004] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Alternative splicing is one of the major sources of the large transcriptional diversity found in human cells. Splicing variants have been shown to be associated with features like spreading and progression in several human tumors. Therefore, such variants may be of great importance as both diagnostic and therapeutic tools. Here, by using a set of criteria regarding the expression pattern of splicing variants and statistical analyses, we were able to screen the genome for exons overexpressed in tumors of specific tissues. However, as in other analyses attempting to identify tumor-associated variants, our list of candidates was seriously inflated with cases of genes differentially expressed in tumors. To exclude these cases and increase the probability of finding bona fide regulated splicing variants, we performed a serial analysis of gene expression (SAGE), excluding those genes that were shown to be upregulated in tumors. This allowed us to predict the overexpression of single exons in specific tumors. Our final group of candidates includes 1,386 exons belonging to 638 genes. Experimental validation of a few candidates in normal tissue, tumor cell lines, and patient samples suggests that most of these candidates are indeed tumor-associated exons. Further functional classification of our candidate genes shows that our final list is slightly inflated with cancer-related genes.
Collapse
|
26
|
Atanelov L, Xu Q, Rad R, Lee C. Targeting alternatively spliced sequence features for cancer diagnosis and therapeutics. J Gastroenterol 2005; 40 Suppl 16:14-20. [PMID: 15902958 DOI: 10.1007/bf02990573] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Alternative splicing is emerging as a major new mechanism of functional regulation in mammals, and there is increasing evidence that human cancers often involve significant changes in alternative splicing. In some cases, these changes contribute functionally to the maintenance of the transformed state and could be useful as novel targets for anticancer therapy. In other cases, they reflect changes due to tumorigenesis and could be useful for diagnostic purposes. Fundamentally, alternative splicing offers a novel opportunity to target individual subregions of a gene product that are preferentially expressed in tumors and which are not found in isoforms of the same gene found preferentially in normal tissues.
Collapse
Affiliation(s)
- Levan Atanelov
- Institute for Genomics and Proteomics, Molecular Biology Institute, and Department of Chemistry and Biochemistry, University of California, Los Angeles, Los Angeles, CA 90095-1570, USA
| | | | | | | |
Collapse
|
27
|
Renaudineau Y, Nédellec S, Berthou C, Lydyard PM, Youinou P, Pers JO. Role of B-cell antigen receptor-associated molecules and lipid rafts in CD5-induced apoptosis of B CLL cells. Leukemia 2005; 19:223-9. [PMID: 15618965 DOI: 10.1038/sj.leu.2403601] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
A total of 40 patients with B-CLL were investigated for CD5-triggered apoptosis and categorized as 20 resistant (group I) and 20 sensitive patients (group II). The densities of surface IgM (sIgM) and CD5 were lower in group I than group II, as were the percentages of CD79b+, CD38+, and Zap70-expressing B cells. CD5 signaling was mediated through the BCR in group II B cells, as established by coimmunoprecipitation of CD5 and CD79a and tyrosine phosphorylation of CD79a. Following colocalization of CD5 and sIgM in membrane lipid rafts (LRs), Syk became associated with these molecules, whereas SHP-1 was uncoupled from CD5. Nonresponsiveness to CD5 cross-linking in group I was ascribed to three possible abnormalities, and defined as three subgroups of patients. In subgroups Ia and Ib, CD5 and sIgM colocalized within the LRs. SHP-1 remained attached to the BCR in subgroup Ia, but not in subgroup Ib, where signal transduction was associated with an excess of truncated CD79b. In subgroup Ic, CD5 and sIgM segregated into different LRs, resulting in no signaling of apoptosis.
Collapse
MESH Headings
- Antigens, CD/genetics
- Antigens, CD/immunology
- Apoptosis
- B-Lymphocytes/immunology
- CD5 Antigens/immunology
- CD79 Antigens
- Cell Culture Techniques
- Flow Cytometry
- Humans
- Leukemia, Lymphocytic, Chronic, B-Cell/blood
- Leukemia, Lymphocytic, Chronic, B-Cell/immunology
- Membrane Microdomains/physiology
- Receptors, Antigen, B-Cell/physiology
- Transcription, Genetic
Collapse
Affiliation(s)
- Y Renaudineau
- Laboratory of Immunology, Brest University Medical School, Brest, France.
| | | | | | | | | | | |
Collapse
|
28
|
Hauge H, Patzke S, Delabie J, Aasheim HC. Characterization of a novel immunoglobulin-like domain containing receptor. Biochem Biophys Res Commun 2004; 323:970-8. [PMID: 15381095 DOI: 10.1016/j.bbrc.2004.08.188] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2004] [Indexed: 10/26/2022]
Abstract
A not yet described gene was identified in a lymphoma specific subtraction strategy. Three splice variants of this gene denoted immunoglobulin-like domain containing receptor 1 (ILDR1) were identified and characterized. Cellular localization studies showed membrane-association for two of the variants, while the third was cytoplasmic and appeared to translocate to the membrane upon co-expression with any of the other two isoforms. ILDR1 shows approximately 30% homology to a recently described protein from rat, lipolysis stimulated receptor, that has been shown to bind low-density lipoprotein. The gene encoding ILDR1 is localized to chromosome 3q21.1 and it is expressed in prostate, testis, pancreas, kidney, liver, and heart. Interestingly, the shortest transcript corresponding to the cytoplasmic variant could only be detected in lymphoma samples and not in normal tissues or cell lines tested. The expression of this variant may therefore be related to the development and/or progression of cancer.
Collapse
Affiliation(s)
- Helena Hauge
- Department of Immunology, The Norwegian Radium Hospital, Oslo, Norway
| | | | | | | |
Collapse
|
29
|
Chen L, Apgar J, Huynh L, Dicker F, Giago-McGahan T, Rassenti L, Weiss A, Kipps TJ. ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia. Blood 2004; 105:2036-41. [PMID: 15514014 DOI: 10.1182/blood-2004-05-1715] [Citation(s) in RCA: 178] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Chronic lymphocytic leukemia (CLL) B cells that express unmutated immunoglobulin heavy-chain variable region genes (IgV(H)) generally express ZAP-70, in contrast to normal B cells or most CLL cases with mutated IgV(H). Following IgM ligation, ZAP-70+ CLL cells had significantly higher levels of phosphorylated p72(Syk), BLNK, and phospholipase-Cgamma (PLCgamma) and had greater[Ca2+]i flux than did ZAP-70-negative CLL cases, including unusual ZAP-70-negative cases with unmutated IgV(H). IgM ligation of ZAP-70-negative CLL B cells infected with an adenovirus vector encoding ZAP-70 induced significantly greater levels of phosphorylated p72(Syk), BLNK, and PLCgamma and had greater[Ca2+]i flux than did similarly stimulated, noninfected CLL cells or CLL cells infected with a control adenovirus vector. We conclude that expression of ZAP-70 in CLL allows for more effective IgM signaling in CLL B cells, a feature that could contribute to the relatively aggressive clinical behavior generally associated with CLL cells that express unmutated IgV(H).
Collapse
Affiliation(s)
- Liguang Chen
- Division of Hematology/Oncology, Department of Medicine, University of California, San Diego, 9500 Gilman Dr, UCSD School of Medicine, La Jolla, CA 92093, USA
| | | | | | | | | | | | | | | |
Collapse
|
30
|
Caligaris-Cappio F, Ghia P. The nature and origin of the B-chronic lymphocytic leukemia cell: a tentative model. Hematol Oncol Clin North Am 2004; 18:849-62, viii. [PMID: 15325702 DOI: 10.1016/j.hoc.2004.04.004] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Chronic lymphocytic leukemia cells have the profile of antigen (Ag) activated memory B cells but also show a constellation of T-cell-associated properties. We suggest that the early transforming events may occur in an early lymphoid progenitor. This precursor differentiates into a mature B cell that, though retaining T-cell features, has a functional B-cell receptor that may allow Ag intervention to trigger clonal expansion. This model has to cope with the existence of at least two subsets of the disease as defined by their IgVH genes mutational status. Mutated cases have a lower capacity to interact with Ag and are reminiscent of anergic cells. This explains their less harmful behavior as compared with unmutated case, which have a more aggressive potential likely because they had the opportunity to acquire additional chromosomal aberrations after repeated rounds of Ag stimulation and replication.
Collapse
|
31
|
Kofler DM, Büning H, Mayr C, Bund D, Baumert J, Hallek M, Wendtner CM. Engagement of the B-cell antigen receptor (BCR) allows efficient transduction of ZAP-70-positive primary B-CLL cells by recombinant adeno-associated virus (rAAV) vectors. Gene Ther 2004; 11:1416-24. [PMID: 15269708 DOI: 10.1038/sj.gt.3302279] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Engagement of the B-cell antigen receptor (BCR) by crosslinking of the surface immunoglobulin (sIg) homodimer was studied for recombinant adeno-associated virus (rAAV)-mediated gene transfer into B-cell chronic lymphocytic leukaemia (B-CLL) cells. Leukemic cells obtained from 20 patients were stimulated with anti-sIg-directed antibodies and transduced with rAAV vectors coding for enhanced green fluorescent protein (EGFP) (AAV/EGFP) or CD40L (AAV/CD40L). Transduction of B-CLL cells was enhanced after BCR engagement compared to unstimulated controls (P=0.0356). BCR crosslinking induced a significant, dose- and time-dependent upregulation of heparan sulfate proteoglycan (HSPG), the primary receptor for AAV, on B-CLL cells (mean: 38.2 versus 1.7%; P=0.0006). A correlation of HSPG expression after BCR crosslinking with transduction efficiency by AAV/EGFP (P=0.0153) and AAV/CD40L (P=0.0347) was observed. High expression of zeta-associated protein 70 (ZAP-70) in B-CLL cells correlated with a better transduction efficiency by AAV/EGFP (P<0.0001) and AAV/CD40L (P=0.002), respectively: 48 h after transduction of ZAP-70-positive samples, transgene expression was seen in a mean of 33.8% (s.e.m. 3.7%) and 28.9% (s.e.m. 6.7%) of cells, respectively, and could be specifically blocked by heparin, a soluble competitor of HSPG (P<0.0001). In summary, engagement of the BCR on ZAP-70 positive B-CLL cells allows efficient rAAV-mediated gene delivery.
Collapse
MESH Headings
- CD40 Ligand/genetics
- Cell Line, Tumor
- Dependovirus/genetics
- Flow Cytometry
- Gene Expression
- Genetic Therapy/methods
- Genetic Vectors/administration & dosage
- Genetic Vectors/genetics
- Genetic Vectors/metabolism
- Heparan Sulfate Proteoglycans/genetics
- Heparan Sulfate Proteoglycans/metabolism
- Heparin/metabolism
- Heparin/pharmacology
- Humans
- Immunophenotyping/methods
- Leukemia, Lymphocytic, Chronic, B-Cell/metabolism
- Leukemia, Lymphocytic, Chronic, B-Cell/therapy
- Protein-Tyrosine Kinases/genetics
- Receptors, Antigen, B-Cell/metabolism
- Recombinant Fusion Proteins/administration & dosage
- Recombinant Fusion Proteins/genetics
- Recombinant Fusion Proteins/metabolism
- Transduction, Genetic/methods
- ZAP-70 Protein-Tyrosine Kinase
Collapse
Affiliation(s)
- D M Kofler
- KKG Gene Therapy, GSF-National Research Center for Environment and Health, Munich, Germany
| | | | | | | | | | | | | |
Collapse
|
32
|
Stevenson FK, Caligaris-Cappio F. Chronic lymphocytic leukemia: revelations from the B-cell receptor. Blood 2004; 103:4389-95. [PMID: 14962897 DOI: 10.1182/blood-2003-12-4312] [Citation(s) in RCA: 305] [Impact Index Per Article: 15.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Abstract
The finding that chronic lymphocytic leukemia (CLL) consists of 2 clinical subsets, distinguished by the incidence of somatic mutations in the immunoglobulin (Ig) variable region (V) genes, has clearly linked prognosis to biology. Antigen encounter by the cell of origin is indicated in both subsets by selective but distinct expression of V genes, with evidence for continuing stimulation after transformation. The key to distinctive tumor behavior likely relates to the differential ability of the B-cell receptor (BCR) to respond. Both subsets may be undergoing low-level signaling in vivo, although analysis of blood cells limits knowledge of critical events in the tissue microenvironment. Analysis of signal competence in vitro reveals that unmutated CLL generally continues to respond, whereas mutated CLL is anergized. Differential responsiveness may reflect the increased ability of post-germinal center B cells to be triggered by antigen, leading to long-term anergy. This could minimize cell division in mutated CLL and account for prognostic differences. Unifying features of CLL include low responsiveness, expression of CD25, and production of immunosuppressive cytokines. These properties are reminiscent of regulatory T cells and suggest that the cell of origin of CLL might be a regulatory B cell. Continuing regulatory activity, mediated via autoantigen, could suppress Ig production and lead to disease-associated hypogammaglobulinemia. (Blood. 2004;103:4389-4395)
Collapse
Affiliation(s)
- Freda K Stevenson
- Molecular Immunology Group, Tenovus Laboratory, Cancer Sciences Division, Southampton University Hospitals Trust, Southampton SO16 6YD, United Kingdom.
| | | |
Collapse
|
33
|
Vanhentenrijk V, De Wolf-Peeters C, Wlodarska I. Comparative expressed sequence hybridization studies of hairy cell leukemia show uniform expression profile and imprint of spleen signature. Blood 2004; 104:250-5. [PMID: 15016649 DOI: 10.1182/blood-2004-01-0181] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
Comparative expressed sequence hybridization (CESH) to chromosomes is a recently introduced technique that identifies chromosomal regions corresponding to a differential gene expression. This technique is analogous to comparative genomic hybridization (CGH) that detects genomic imbalances. We applied CESH for the study of hairy cell leukemia (HCL), a disorder with a largely unknown expression profile. Twelve HCL cases with spleen involvement were investigated by CESH and CGH. While the latter analysis identified only a few nonrecurrent genomic imbalances, CESH showed a consistent expression profile in all HCL cases. In addition, pairing normal spleen with normal lymph node, a "spleen signature" was established by CESH. This signature most likely reflects the expression profile of spleen-specific components, such as the sinusoidal lining cells from the red pulp and the marginal zone B cells from the white pulp. Imprint of the spleen signature was found in the HCL expression profile, suggesting that HCL may originate from a particular B-cell subset present in these splenic components. Besides pairing HCL with normal lymph node and spleen, we identified an "HCL signature" comprising several chromosome regions with altered expression. The most significantly underexpressed regions include 3p24, 3p21, 3q13.3-q22, 4p16, 11q23, 14q22-q24, 15q21-q22, 15q24-q25, and 17q22-q24; and 13q31 and Xq13.3-q21 were the most significantly overexpressed. These regions possibly harbor genes related to the biology and the pathogenesis of HCL. Their identification warrants further molecular investigations.
Collapse
Affiliation(s)
- Vera Vanhentenrijk
- Division of Morphology and Molecualr Pathology and Center for Human Genetics, Katholieke Universiteit Leuven, Belgium
| | | | | |
Collapse
|
34
|
MESH Headings
- B-Lymphocytes/immunology
- B-Lymphocytes/pathology
- CD4-Positive T-Lymphocytes/immunology
- CD40 Ligand/immunology
- Cell Division
- Disease Progression
- Humans
- Immunotherapy, Adoptive
- Leukemia, Lymphocytic, Chronic, B-Cell/immunology
- Leukemia, Lymphocytic, Chronic, B-Cell/pathology
- Leukemia, Lymphocytic, Chronic, B-Cell/therapy
- Lymphocyte Activation
- Models, Immunological
- Stromal Cells/pathology
Collapse
|
35
|
Xu Q, Lee C. Discovery of novel splice forms and functional analysis of cancer-specific alternative splicing in human expressed sequences. Nucleic Acids Res 2003; 31:5635-43. [PMID: 14500827 PMCID: PMC206480 DOI: 10.1093/nar/gkg786] [Citation(s) in RCA: 151] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
We report here a genome-wide analysis of alternative splicing in 2 million human expressed sequence tags (ESTs), to identify splice forms that are up-regulated in tumors relative to normal tissues. We found strong evidence (P < 0.01) of cancer-specific splice variants in 316 human genes. In total, 78% of the cancer-specific splice forms we detected are confirmed by human-curated mRNA sequences, indicating that our results are not due to random mis-splicing in tumors; 73% of the genes showed the same cancer-specific splicing changes in tissue-matched tumor versus normal datasets, indicating that the vast majority of these changes are associated with tumorigenesis, not tissue specificity. We have confirmed our EST results in an independent set of experimental data provided by human-curated mRNAs (P-value 10(-5.7)). Moreover, the majority of the genes we detected have functions associated with cancer (P-value 0.0007), suggesting that their altered splicing may play a functional role in cancer. Analysis of the types of cancer-specific splicing shifts suggests that many of these shifts act by disrupting a tumor suppressor function. Sur prisingly, our data show that for a large number (190 in this study) of cancer-associated genes cloned originally from tumors, there exists a previously uncharacterized splice form of the gene that appears to be predominant in normal tissue.
Collapse
Affiliation(s)
- Qiang Xu
- Institute for Genomics and Proteomics, Molecular Biology Institute and Department of Chemistry & Biochemistry, University of California, Los Angeles, Los Angeles, CA 90095-1570, USA
| | | |
Collapse
|
36
|
Deaglio S, Capobianco A, Bergui L, Dürig J, Morabito F, Dührsen U, Malavasi F. CD38 is a signaling molecule in B-cell chronic lymphocytic leukemia cells. Blood 2003; 102:2146-55. [PMID: 12763926 DOI: 10.1182/blood-2003-03-0989] [Citation(s) in RCA: 141] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
The prognosis for patients with B-cell chronic lymphocytic leukemia (B-CLL) is generally less favorable for those expressing CD38. Our working hypothesis is that CD38 is not merely a marker in B-CLL, but that it plays a receptor role with pathogenetic potential ruling the proliferation of the malignant clone. CD38 levels were generally low in the patients examined and monoclonal antibody (mAb) ligation was inefficient in signaling. Other cellular models indicated that molecular density and surface organization are critical for CD38 functionality. Interleukin 2 (IL-2) induced a marked up-modulation and surface rearrangement of CD38 in all the patients studied. On reaching a specific expression threshold, CD38 becomes an efficient receptor in purified B-CLL cells. Indeed, mAb ligation is followed by Ca2+ fluxes and by a markedly increased proliferation. The unsuitability of CD38 to perform as a receptor is obviated through close interaction with the B-cell-receptor (BCR) complex and CD19. On mAb binding, CD38 translocates to the membrane lipid microdomains, as shown by a colocalization with the GM1 ganglioside and with CD81, a raft-resident protein. Finally, CD38 signaling in IL-2-treated B-CLL cells prolonged survival and induced the appearance of plasmablasts, providing a pathogenetic hypothesis for the occurrence of Richter syndrome.
Collapse
MESH Headings
- ADP-ribosyl Cyclase/metabolism
- ADP-ribosyl Cyclase 1
- Aged
- Antibodies, Monoclonal/metabolism
- Antibodies, Monoclonal/pharmacology
- Antigens, CD/metabolism
- Antigens, CD19/metabolism
- Apoptosis/immunology
- B-Lymphocytes/cytology
- B-Lymphocytes/metabolism
- Cell Division/immunology
- Cell Survival/immunology
- Cells, Cultured
- Cytokines/metabolism
- Female
- Humans
- Interleukin-2/pharmacology
- Leukemia, B-Cell/metabolism
- Leukemia, B-Cell/pathology
- Leukemia, Lymphocytic, Chronic, B-Cell/metabolism
- Leukemia, Lymphocytic, Chronic, B-Cell/pathology
- Male
- Membrane Glycoproteins
- Membrane Microdomains/immunology
- Membrane Microdomains/metabolism
- Middle Aged
- Prognosis
- Signal Transduction/immunology
Collapse
Affiliation(s)
- Silvia Deaglio
- Laboratory of Immunogenetics, Department of Genetics, Biology and Biochemistry, via Santena 19, 10126 Turin, Italy.
| | | | | | | | | | | | | |
Collapse
|
37
|
Abstract
B-cell chronic lymphocytic leukemia increasingly is being recognized as a useful model disease with which to study more general processes involved in the evolution of neoplastic disease. The accessibility of the tumor cells and the capacity to confirm their clonal relatedness allow for evaluation of the processes associated with neoplastic transformation and/or disease progression. Recent studies have provided fascinating insight into the potential pathogenesis and pathophysiology of this disease. In addition, features of leukemia cells have been identified that can distinguish subsets of patients that have different tendencies for disease progression. Gene expression studies have identified a relatively small number of genes that are differentially expressed between these subsets, allowing for focused attention on proteins that might contribute to the noted differences in clinical behavior. Finally, recognition that chronic lymphocytic leukemia cells depend upon specific microenvironmental growth and survival factors identifies novel targets for disease intervention. This article focuses on the reports of the past year that have contributed to these areas of active research on chronic lymphocytic leukemia, the most common adult leukemia in Western societies.
Collapse
MESH Headings
- Gene Expression Regulation, Neoplastic/immunology
- Humans
- Immune System/pathology
- Leukemia, Lymphocytic, Chronic, B-Cell/complications
- Leukemia, Lymphocytic, Chronic, B-Cell/etiology
- Leukemia, Lymphocytic, Chronic, B-Cell/immunology
- Signal Transduction/immunology
Collapse
Affiliation(s)
- Thomas J Kipps
- Division of Hematology/Oncology, department of Medicine, UCSD School of Medicine, University of California, San Diego, California, USA.
| |
Collapse
|
38
|
Payelle-Brogard B, Magnac C, Oppezzo P, Dumas G, Dighiero G, Vuillier F. Retention and defective assembly of the B-cell receptor in the endoplasmic reticulum of chronic lymphocytic leukaemia B cells cannot be reverted upon CD40 ligand stimulation. Leukemia 2003; 17:1196-9. [PMID: 12764393 DOI: 10.1038/sj.leu.2402944] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
MESH Headings
- Antigens, CD/genetics
- Antigens, CD/metabolism
- B-Lymphocytes/metabolism
- B-Lymphocytes/pathology
- B7-1 Antigen/metabolism
- B7-2 Antigen
- CD40 Ligand/genetics
- CD40 Ligand/metabolism
- CD79 Antigens
- Case-Control Studies
- Endoplasmic Reticulum/metabolism
- Gene Expression Regulation, Leukemic
- Humans
- Immunoglobulin M/metabolism
- Leukemia, Lymphocytic, Chronic, B-Cell/complications
- Leukemia, Lymphocytic, Chronic, B-Cell/genetics
- Lymphocyte Activation
- Membrane Glycoproteins/metabolism
- Receptors, Antigen, B-Cell/metabolism
Collapse
|